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Abstract
Purpose 18F-Fluorocholine (FCH) and 11C-acetate (ACE)
PET are widely used for detection of recurrent prostate cancer
(PC).We present the first results of a comparative, prospective
PET/CT study of both tracers evaluated in the same patients
presenting with recurrence and low PSA to compare the
diagnostic information provided by the two tracers.
Methods The study group comprised 23 patients studied for a
rising PSA level after radical prostatectomy (RP, 7 patients,
PSA ≤3 ng/ml), curative radiotherapy (RT, 7 patients, PSA
≤5 ng/ml) or RP and salvage RT (9 patients, PSA ≤5 ng/ml).
Both FCH and ACE PET/CT scans were performed in a
random sequence a median of 4 days (range 0 to 11 days)
apart. FCH PET/CT was started at injection (307±16 MBq)
with a 10-min dynamic acquisition of the prostate bed, follow-
ed by a whole-body PETscan and late (45 min) imaging of the
pelvis. ACE PET/CTwas performed as a double whole-body
PETscan starting 5 and 22min after injection (994±72MBq),
and a late view (45 min) of the prostate bed. PET/CT scans
were blindly reviewed by two independent pairs of two expe-
rienced nuclear medicine physicians, discordant subgroup
results being discussed to reach a consensus for positive,
negative end equivocal results.
Results PET results were concordant in 88 out of 92 local,
regional and distant findings (Cohen’s kappa 0.929). In par-
ticular, results were concordant in all patients concerning local
status, bone metastases and distant findings. Lymph-node
results were concordant in 19 patients and different in 4 patients.
On a per-patient basis results were concordant in 22 of 23
patients (14 positive, 5 negative and 3 equivocal). In only one
patient was ACE PET/CT positive for nodal metastases while
FCH PET/CT was overall negative; interestingly, the ACE-
positive and FCH-negative lymph nodes became positive in a
second FCH PET/CT scan performed a few months later.
Conclusion Overall, ACE and FCH PET/CT showed excel-
lent concordance, on both a per-lesion and a per-patient basis,
suggesting that both tracers perform equally for recurrent
prostate cancer staging.
Keywords 11C-Acetate . 18F-Fluorocholine . PET/CT .
Intraindividual comparison . Prostate cancer recurrence
Introduction
Promising results in the detection of recurrent prostate cancer
(PC) have been obtained with different PET tracers such as 11C-
acetate (ACE), 11C-choline, and 18F-fluorocholine (FCH) [1, 2].
Prostate-specific antigen (PSA) is a sensitive early blood
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marker for PC recurrence particularly after radical prostatecto-
my (RP) when PSA is expected to become undetectable. After
surgery recurrence of cancer can be suspected at the earliest rise
in PSA [3, 4]. PSA values of between 0.01 and 0.1 ng/ml after
RP represent a probability for a further rise in PSA and tumour
recurrence of 67 %, and this probability rises to 90 %with PSA
values >0.1 ng/ml [5]. After primary radiation therapy (RT), a
PSA value ≥2 ng/ml above the nadir is a robust standard for
recurrence reliably predicting distant metastases, and cause-
specific and overall mortality [6].
In this study we compared the performance of ACE and
FCH for diagnosing early recurrent PC by assessing the cor-
relation between the blinded reading of the two imaging sets.
Early localization of recurrences might allow a still curative
salvage treatment to be undertaken [7], although a consensus
has not yet been defined for the indication for PET/CT in this
situation [8–10]. Our group favours PET/CT very early after
the definition of recurrence. Having experience with both
ACE [11] and FCH [12–14], we aimed to evaluate both tracers
in a comparative assessment to determine if one is superior to
the other in the setting of early biochemical recurrence of PC.
Materials and methods
This prospective feasibility study was approved by the Ethics
Committee of the University Hospital of Geneva, Swissmedic
and OFSP, Section of Radioprotection, and was performed in
conformance with Swiss legislation and Good Clinical Practice
(GCP) rules and with the ethical standards of the Declaration of
Helsinki and later amendments. All patients provided written
informed consent to the study protocol foreseeing two PET/CT
scans, one with FCH and the other with ACE in random order. In
case of positive findings, the patients were investigated by com-
plementary imaging (MR, bone scintigraphy) and biopsying the
suspected local relapse, when indicated and feasible.
Patients
Up to the time of this report, 23 patients had been studied. The
patients’ characteristics are summarized in Table 1.
Inclusion criteria were:
– biochemical relapse after RP (group A), curative RTwith
or without androgen deprivation (AD, group B) or RP
and salvage RT (with or without AD, group C)
– PSAvalues ≤3 ng/ml for group A and C and ≤5 ng/ml for
group B
– signed written informed consent
Exclusion criteria were:
– patients under AD
– patients with active major inflammatory/infectious
process
Compliance with further investigations (biopsy of
suspected recurrence, complementary MR and bone scintig-
raphy) was not an inclusion criterion. Seven patients were
included in group A, 7 in group B and 9 in group C. Mean
PSA values at study entry were lowest in group A (1.1±
0.9 ng/ml), highest in group B (3.5±0.9 ng/ml), and interme-
diate in group C (2.4±1.0 ng/ml).
Dual PET/CT studies
FCH and ACE PET/CTstudies were performed according to a
random sequence in 21 patients, while 2 patients had both
PET/CT scans performed on the same day (ACE in the morn-
ing and FCH in the afternoon, the two studies separated by a
minimum of 2.5 h). The median interval between the two
scans was 4.0 days (range 0 to 11 days).
18F-Fluorocholine PET/CT
FCH (N ,N-dimethyl-N-[18F]fluoromethylethanolammonium)
was prepared according to GMP rules at AAA (Advanced
Accelerator Applications), St Genis-Poully, France.
Dual PET/CTstudies were performed on either a Biograph 64
scanner (18 patients) or a Biograph 16 scanner (5 patients)
(Siemens Medical Solutions, Erlangen, Germany). All patients
fasted for at least 4 h before the FCH andACEPETstudies. After
bladder voiding, patients underwent an initial low-dose CT scan
from the mid thigh to the skull performed under a standard
protocol (arms held above the head and shallow breathing) using
120 kVp, 60 mAs, pitch 1.5 and 1 s per rotation. Under these
conditions, the mean effective radiation dose for an adult patient
was estimated at 4.5 mSv, as calculated using the IMPACT CT
patient dosimetry calculator (http://www.impactscan.org/
ctdosimetry.htm).
After the CT scan, patients received a standard activity of
307 ± 16 MBq 18F-FCH injected intravenously, and a contin-
uous list-mode PETacquisition centred on the prostate bed was
recorded over 10 min starting immediately with the tracer
injection. The 10-min list mode data were used for generating
3 × 3-min time frames corresponding to 0 to 3 min, 3 to 6 min
and 6 to 9 min after injection. Following the list-mode acquisi-
tion, a standard whole-body PETstudy was performed from the
mid thigh to the skull over seven to eight bed positions of 3 to
4 min each depending on patient size and weight. Two addi-
tional late images of 5 min each of the pelvis were acquired
immediately after the whole-body PETscan (about 45 min after
tracer injection).
Following Fourier rebinning and model-based scatter
correction, PET images were reconstructed using two-
dimensional iterative normalized attenuation-weighted
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ordered subsets expectation maximization (NAW-OSEM)
[15]. The CT-based attenuation map was used to correct
emission data. The default reconstruction parameters of four
iterations and eight subsets followed by a postprocessing
gaussian filter (kernel size 5 mm, full-width at half-
maximum) were applied. Images of the three phases of
FCH PET/CT are shown in Fig. 1.
11C-Acetate PET/CT
ACE was prepared at the Cyclotron Unit, University Hospital of
Geneva, according to GMP rules. For the ACE PET/CT scan,
which was identical to the FCH PET scan performed either on
the Biograph 64 (18 patients) or the Biograph 16 (5 patients),
patients fasted for at least 4 h before the study. After bladder
voiding, patients received a standard activity of 994+ 72 MBq
ACE injected intravenously. After ACE injection they underwent
a low-dose CT scan from the mid thigh to the skull performed
under identical conditions to those used for the FCH PET scan
using 120 kVp, 60 mAs, pitch 1.5 and 1 s per rotation.
A first whole-body PET study was performed 5 min after
tracer injection from the mid thigh to the skull over seven to
eight bed positions of 2 min each, followed immediately
(about 22 min after injection) by a second whole-body PET
scan of 3 min per bed position and finally a late PET scan of
the prostate bed was recorded about 45 min after injection.
ACE PET images were reconstructed using the same proce-
dure described above for FCH PET. Images of the three phases
of ACE PET/CT are shown in Fig. 1.
PET/CT interpretation
Each patient's PET/CT scans were interpreted blindly by two
pairs of two experienced nuclear medicine physicians who grad-
ed either the FCH or ACE PET scans for the presence of
recurrent tumour as positive, equivocal or negative. FCH PET
scanswere graded according to the typical time-course of activity
in malignant and benign lesions. Focal FCH hyperactivity above
background that persisted throughout the examination with typ-
ical kinetics was considered a positive lesion [13]. For the ACE
PET scans, focal ACE hyperactivity confirmed in the first and
secondwhole-body scanwas considered positive. The thirdACE
acquisition centred on the prostate bed was not retained for
interpretation since hyperactivities decreased in all patients to a
Table 1 Characteristics of 23
patients according to initial
treatment
Characteristic Radical
prostatectomy
Primary radiotherapy
with or without androgen deprivation
Radical prostatectomy
and salvage radiotherapy
Number of patients 7 7 9
Age (years)
Mean 67.4
SD 7.5
Range 51.0 to 80.4
Initial stage, n
T1c 0 1 0
T2a 0 1 0
T2b 0 1 1
T2c 6 0 2
T3a 0 3 3
T3b 1 1 3
Gleason score summed, n
6 (low grade) 2 1 1
7 (intermediate grade) 4 4 4
8 or 9 (high grade) 1 2 4
PSA (ng/ml)
At diagnosis
Mean 11.1 20.3 15.7
SD 4.8 7.7 9.5
Nadir
Mean 0.1 0.7 0.2
SD 0.2 0.7 0.2
At PET
Mean 1.1 3.5 2.4
SD 0.9 0.9 1.0
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marked degree. Negative ACE and FCH PET scans were those
that did not show any focal persistent activity higher than back-
ground. Equivocal was defined as any lesion with an activity
between the two categories “positive” and “negative”.
Specifically:
– Local relapses corresponded to focal, persistent uptake
over the three FCH sequences and the two ACE se-
quences in the prostate or prostatic bed. In order to avoid
possible interference of bladder activity, particularly for
FCH PET, on the assessment of local relapse after RP, we
systematically assessed early dynamic images acquired
before urine accumulation [13].
– Lymph nodes were considered positive if they showed
persistent uptake over the three FCH sequences and the
two ACE sequences, higher than surrounding tissue.
Inguinal lymph nodes that showed transient tracer
uptake and presenting a lipid centre on CTwere interpreted
as negative.
– CT images were used for localization and morphological
analysis, discriminating between intestinal and lymph
node uptakes and allowing the characterization of lesions,
such as bone hypodensity or hyperdensity and lung
nodules.
Maximum standard uptake values (SUVmax) were calcu-
lated within regions of interest drawn over focal hyperactiv-
ities using a standard formula [16]. The reported values were
measured on the whole-body FCH PET/CT study and on the
first whole-body ACE PET/CT study. SUVmax values were
evaluated since SUVmax is widely used in the literature and
because it is not dependent on lesion size or operator. Since
the two PET/CT scanners used in this study were from the
same provider (Siemens) and had been installed simultaneous-
ly, and acquisition, treatment protocols and software evalua-
tion were identical, images and SUV calculations were
comparable.
To compare the quantitative information provided by the
two PET/CT scanners, we report the SUVmax of the positive
lesions found in the two studies. In order to provide a measure
of the contrast provided by the ACE and FCH PET images we
also calculated target-to-background ratios (TBR). As a back-
ground measure with a high reproducibility across studies we
chose the blood-pool activity in the abdominal aorta.
Fig. 1 Three-phase FCH and
three-phase ACE PET/CT
showing concordant local
recurrence (arrows)
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Furthermore, a Jaszack phantom-based calibration was carried
out to ensure compatibility between the two scanners. A
radiologist interpreted the low-dose CT scans for distant sites.
Standard of reference
All findings were evaluated on both PET and CT images
acquired in the same session. Thus, CT images without con-
trast enhancement were consistently available and allowed
identification of lymph nodes and distant unrelated findings.
Asmentioned above, if findings were positive complementary
imaging with MR and bone scintigraphy and biopsies of the
suspected local recurrences were performed, when indicated
and feasible. Planned patient follow-up was 2 years, and at the
time of this report follow-up was ongoing with a current
median of 11 months (range 1 to 20 months).
Statistical analysis
We measured the agreement between the two tracers consid-
ering the results of each imaging test as positive, negative or
equivocal for local recurrence, locoregional nodal status, bone
metastasis and other distant findings (lung and other organs),
by using Cohen’s kappa coefficient [17]. We also used
Cohen’s kappa to evaluate agreement between the two readers
interpreting the ACE PET and FCH PET data. SUVmax and
TBRs obtained for positive lesions in the two PET/CT studies
were compared using a paired Student’s t test.
Results
Overall, we observed remarkable agreement between the two
PET/CT imaging procedures, with a Cohen’s kappa of 0.929
(above the suggested cut-off of 0.8 [18]). The interrater agree-
ment was slightly lower for ACE (0.657) than for FCH (0.771),
but in both cases was above the conventionally accepted thresh-
old of 0.6 for substantial interrater agreement [18].
For both PET/CT studies, positive, equivocal, or negative
results on aper-patient basiswere identical in 22patients (Table 2).
In only one patient was an ACE PET/CT scan positive for nodal
metastases while the corresponding FCH PET/CT scan was
negative. In a second FCHPET/CTscan performed a fewmonths
later (once the PSA value had increased from 3.84 to 15 ng/ml),
the previously negative lymph nodes this time showed tracer
take-up reproducing the positive result of the previous ACE
Table 2 PET results in 23 patients with relapse (on a per-patient basis) according to initial treatment and PSA value at the time of the PET scan
PSA (ng/ml) Radical prostatectomy Primary radiotherapy
with or without
androgen deprivation
Radical prostatectomy and
salvage radiotherapy
All
Positive Equivocal Negative Positive Equivocal Positive Negative Discordant Positive Equivocal Negative Discordant
<1 2 1 2 1 3 (50 %) 1 2
1–3 2 2 4 1 6 (67 %) 3
>3–5 – 3 2 2 1a 5 (63 %) 2 0 1
All 2 1 4 5 2 7 1 1 14 (61 %) 3 5 1
a Patient positive on ACE PET/CT and negative on FCH PET/CT
Table 3 PET results in 23 patients with relapse (on a per-patient basis) according to initial treatment and PSA doubling time
PSA doubling
time (months)
Radical prostatectomy Primary
radiotherapy with or
without androgen
deprivation
Radical prostatectomy
and salvage radiotherapy
All
Positive Equivocal Negative Positive Equivocal Positive Negative Discordant Positive Equivocal Negative Discordant
<5 1 2 4 1 4 (50 %) 1 2 1
5–10 1 3 3 1 6 (75 %) 2
>10 2a 1 2 2 4 (57 %) 2 1
All 2 1 4 5 2 7 1 1 14 (61 %) 3 5 1
a Two patients in the surgery group had a positive PETscan (one local, one adenopathy) while presenting with particularly high doubling times of 86 and
35 months and low PSA of 0.96 and 0.4 ng/ml
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PET/CT scan. PET double positivity was lowest in patients with
PSA <1 ng/ml, with three of six patients being positive in this
subgroup. A higher positivity rate was observed in those with a
PSA value between 1 and 3 ng/ml (67 % positive) and a PSA
value between 3 and 5 ng/ml (63 % positive). A correlation
between double PET positivity rate and PSA doubling time was
not observed (Table 3); however, the subgroupswere rather small.
Table 4 summarizes all PET results according to site and
concordance for ACE and FCH PET studies. Both PET/CTs
were similarly positive for local recurrences in 6 patients.
Four out of six local recurrences could be confirmed by the
standard of reference investigations. In particular, three pa-
tients underwent biopsies of the prostate and/or prostatic bed,
which in all patients confirmed the local recurrence, and one
patient had an MR scan which identified a local recurrence
corresponding to the focal uptake visible on PET images. The
two bonemetastases identified in two patients were confirmed
as isolated lesions on CT images and on positive bone scans.
Two examples of concordantly positive imaging for local
recurrence and for bone metastasis are shown in Figs. 1 and
2. Concordant imaging of incidental pathologies was observed
in four patients with both radiotracers positive: a pituitary
tumour (confirmed by MR and subsequently by histology;
Fig. 3), a thyroid nodule (confirmed by ultrasound imaging
and biological evaluation as a parathyroid adenoma), a lung
tumour (confirmed by follow-up CT imaging as a stable
nodule), and a supraclavicular lymph node (visible on CT
images and probably unrelated to the baseline PC). Concor-
dant information concerning lymph node status was obtained
in 19 patients (9 positive, 8 negative, 2 equivocal). An exam-
ple of concordantly positive findings for a pelvic lymph node
is presented in Fig. 4. For positive lymph nodes, the average
SUVmax was 4.8±2.7 and 5.6±2.7 on ACE and FCH PET/
CT, respectively.
Differences between ACE and FCH PET/CT were ob-
served in four patients. Among these, two patients had a
clearly positive lymph node on ACE PET/CT but negative
on FCH PET, as shown in Fig. 5. In these two patients, the
SUVmax values found onACE PET/CTwere 3.3 and 2.9, that
is in the range of lower values for positive lesions. In one
patient a subsequent repeat FCH PET/CT scan confirmed the
earlier ACE PET/CT positivity. In the third patient an external
Table 4 PET results according to localization and concordance between
ACE and FCH PETexpressed as the numbers of double-positive, double-
equivocal, double-negative and discordant PET results per site
Recurrence Concordant PET results Discordant
PET results
Total
per site
Both
positive
Both
equivocal
Both
negative
Local 6 3 14 0 23
Lymph node 9 2 8 4 23
Bone
metastasis
2 0 21 0 23
Total 17a 5 43 4 69
Unrelated
patholo-
gies
4b 0 19 0 23
a Two patients were simultaneously double-positive for lymph nodes and
bone metastases, one patient simultaneously had a double-positive local
recurrence and lymph nodes. With regard to Tables 2 and 3, a total of 14
patients had double-positive PET results.
b Three concordant hyperactivities unrelated to PC were observed in one
hypophysis, one thyroid and one lung.
Fig. 2 Bone lesion concordantly
positive (arrows) on both FCH
and ACE PET/CT
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iliac lymph node was equivocal on ACE PETand negative on
FCH PET. In the fourth patient, retroperitoneal lymph nodes
were equivocal on both FCH and ACE PET/CT, but some
nodes were equivocal with one or the other of the radiotracers
but not with both, although in this patient both PETscans were
performed on the same day. Discordant lymph node PET/CT
findings might occasionally reflect inflammatory situations,
but in one patient an ACE-positive FCH-negative lymph node
had progressed on imaging follow-up, suggesting a possible
but small difference in sensitivity. No comparison with our
standard of reference was available for lymph node status,
given that no biopsy could be performed and the follow-up at
the time of this report was shorter than planned.
The SUVmax values of the concordantly positive lesions
on ACE and FCH PET/CT studies were 4.4±1.7 (mean ± SD)
and 5.3±2, respectively (Table 5). The values were signifi-
cantly different between the two studies (p =0.017). The TBR
values, however, did not differ significantly between the two
studies (4.4±1.7 and 5.1±2.1 on ACE and FCH PET/CT
studies, respectively; p =0.089).
Fig. 3 Pituitary gland
concordantly positive on whole-
body FCH and ACE PET/CT
acquisitions corresponding to a
macroadenoma
Fig. 4 Pelvic lymph node
concordantly positive (arrows)
on both FCH and ACE PET/CT
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Discussion
11C-Choline, 18F-choline and 11C-acetate are major agents for
PET imaging of PC [1, 2]. Only a few intraindividual com-
parisons of PET have been performed with these radiotracers.
11C-Acetate and 11C-choline PET have been directly com-
pared in limited numbers of PC patients [19] and more recent-
ly by PET/CT in bladder cancer patients [20]. Both studies
concluded that the performance of both tracers is similar. It has
been reported that 11C-acetate PET fused retrospectively with
CT and MR scans is essential for the final diagnosis of
recurrent PC, notably for uptake in the prostate region [21].
Our findings are concordant with these results, given that we
had a high rate of histological confirmation of positive local
findings (all patients biopsied showed local recurrence). In
addition, all our studies obtained on an integrated PET/CT
scanner systematically included a whole-body unenhanced
CT scan for localization and morphological analysis, discrim-
inating between intestinal lymph node uptake. We had a
higher rate of negative findings in our study (39 % vs.
10 %), that could be explained by the lower mean PSA at
inclusion (2.3 vs. 6.3 ng/ml),
Acetate and choline are taken up by proliferating cells and
can be transformed to phosphatidylcholine and phosphocholine,
respectively [22, 23]. Transmembrane transport of choline is
dependent on the high-affinity choline transporter [24, 25],
while transport of acetate is dependent on the monocarboxylate
transporter-1 (MTC-1) or sodium-coupled MTC-1 (SMTC1)
[26]. A relationship between 11C-choline and choline kinase
expression has also been described [27], and in that study, this
tracer was highly specific and sensitive for staging pelvic lymph
nodes. Phosphatidylcholine can be incorporated into nascent
cell membranes. In a direct comparison of the two tracers,
uptake was correlated with the tumour cell proliferation rate
measured with tritiated thymidine, with an uptake advantage
being found in the in vitro situation for ACE [22]. However,
acetate can also be metabolized, notably in active musculature
which allows cardiac [28] and striate muscle imaging [29].
Similarly, choline can be oxidized to betain aldehyde and is
Fig. 5 Discordant interaortic
lymph node, negative on FCH
PET/CT (above) and positive on
ACE PET/CT (first whole-body
acquisition, lower row)
Table 5 SUVmax values and TBR for positive findings on ACE or FCH
PET/CT or both
ACE PET/CT FCH PET/CT
SUVmax TBR SUVmax TBR
Target Background Target Background
Prostate
1 4.6 1.1 4.2 5.3 1.1 4.8
2 3.2 1.3 2.5 4.4 1.5 2.9
3 4.3 0.7 6.1 5.5 0.9 6.1
4 3.8 1.4 2.7 5.4 1.3 4.2
5 4 1 4.0 5.2 1.1 4.7
6 5.2 1 5.2 5 1.3 3.8
Lymph nodes
1 6.7 0.9 7.4 9.5 1 9.5
2 4.8 1.5 3.2 4.5 1 4.5
3 1.5 0.6 2.5 3.6 0.8 4.5
4 3.8 1.1 3.5 3.1 0.9 3.4
5 6.6 1 6.6 6.2 1.1 5.6
6 7.9 1.1 7.2 10.4 1 10.4
7 6.2 1.2 5.2 5.6 1 5.6
8 3 1 3.0 4.8 1.3 3.7
9 2.8 0.8 3.5 2.9 1.1 2.6
10 3.3 1.2 2.8 Negative Negative –
11 2.9 1 2.9 Negative Negative –
Bone lesions
1 4.8 0.9 5.3 3.5 1 3.5
2 1.8 0.6 3.0 5.3 0.8 6.6
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therefore taken up particularly in the liver and kidneys [22]. The
uptake of 18F-choline by cells is similar to that of 11C-labelled
choline, but after phosphorylation via choline kinase, the
phospho-18F-choline remains trapped in the cytoplasm without
further metabolism [30]. In the present study, we compared
FCH and ACE PET/CT intraindividually in patients with bio-
chemical recurrence and low PSA values. We sought to deter-
mine whether an indication of higher sensitivity of one or the
other agent would be observed in patients with low PSA levels
or whether both tracers could be complementary. The localiza-
tion of tumour recurrences in patients with low PSA levels is of
clinical interest, since it could allow detection of tumours of
restricted dissemination and therefore amenable to curative
salvage therapy [7].
In contrast to ACE and 11C-choline, FCH is a PET tracer
with a half-life of 110 min and can be prepared on a commer-
cial basis for distribution to PET centres without access to a
cyclotron unit. FCH has become widely available and appears
to be valuable for evaluation of PC patients with biochemical
recurrence [13, 14, 31, 32]. With the use of early dynamic
imaging centred on the prostate bed, the disadvantage of
urinary excretion of 18F can be partially compensated for since
tumour uptake of FCH occurs earlier than urinary excretion
[13, 33]. Furthermore, late imaging with FCH might allow
discrimination between inflammatory lymph nodes and
tumour-infiltrated lymph nodes [13, 33, 34].
ACE has the advantage of a low to only moderate urinary
excretion of 11C, catabolized tracer being exhaled as 11C-CO2.
On the other hand, its short half-life of 20 min does not allow
the wider distribution of this tracer and requires a demanding
and strict organization of tracer production and injection of
patients. ACE PET/CT positivity in early recurrence appears
to be correlated with blood PSA levels [35]. For PSA <1 ng/
ml, different groups have reported detection rates between
18 % and 36 % [36–40]. Positivity rates of FCH PET/CT in
patients with similarly low PSA values are in the same range
as for ACE PET/CT [12, 13, 32], but occasionally a higher
percentage positivity (49 %) has also been reported [41], as
was the case in this study with, however, only a small number
of patients in this group. Nevertheless, only small numbers of
patients have been studied at very low PSA values by both
ACE and FCH PET/CT, and thus comparison of the results
from the literature would not be reliable. In addition, the above
studies underscore the need for a careful intraindividual as-
sessment of FCH versus 11C-choline PET/CT.
The current results show excellent agreement between
FCH and ACE PET/CT. This suggests that both tracers visu-
alize similar features of PC cells either on tracer integration in
lipid synthesis or catabolic energy provision. These concor-
dant data are in line with previous reports on ACE and 11C-
choline [19, 20], implying that FCH would be a valid alterna-
tive to 11C-choline, although this point still needs to be
addressed by a direct comparison.
This study has a main limitation, namely the absence of
adequate follow-up to provide a “standard of reference” for all
PET/CT findings. While the two positive bone findings were
confirmed as bone metastases on CT and bone scintigraphy,
and four of six positive findings for local recurrence could be
confirmed, for other localizations, notably for lymph nodes, a
conclusive interpretation is currently not possible. The limita-
tion of these tracers, however, for lymph node disease is
known [8], as also shown recently for 11C-choline [42] and
reviewed with regard to PET/MR [43]. Thus neither tracer is
the optimal tracer for recurrent PC, particularly for lymph
node evaluation, as uptake is also observed in reactive medi-
astinal and inguinal nodes. It is thus not surprising that the few
discordant data in 4 of 23 patients observed with ACE and
FCH concern lymph node status. A longer follow-up is cur-
rently ongoing and is necessary to address this question. New
tracers targeting specific molecules are currently under
development for the diagnostic evaluation of PC, and some
promising results have been shown in preliminary studies [1,
44, 45].
Conclusion
These findings demonstrated that three-phase FCH PET/CT
and an analogous ACE PET/CT protocol performed equally
for early recurrent PC staging show an overall excellent con-
cordance on a per-patient and a per-lesion basis.
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